Abstract
LDH-C4 (Ldh3) is a member of the lactate dehydrogenase family of isozymes that catalyze the terminal reaction in the glycolytic pathway. In mammals, 3 genes, Idha, Idhb, and Ldhc, encode the subunits that assemble into catalytically active homo- and heterotetramers. Differential expression of these genes determines the lactate dehydrogenase (LDH) isozyme composition of tissues, and, as is well known, A subunits predominate in skeletal muscle and B subunits are abundantly produced in brain and heart, with the Ldh2 isozyme the most abundant form in oocytes. The C peptide can be detected first in pachytene spermatocytes and constitutes the primary LDH of spermatozoa. Originally the Ldhc gene (Ldh3 in terminology applied to murine cells) was considered to be testis specific on the basis of immunochemical, enzymatic, and molecular analyses. Here we report the detection of this isozyme in the murine oocyte and early embryo. Our results indicate that Ldh3 mRNA is transcribed in oocytes and cannot be detected in fertilized eggs. Ldh3 protein, however, persists to the blastocyst stage of embryonic development localizing mainly to the cortex region of oocytes, eggs, zygotes, and embryonic blastomeres.
Original language | English (US) |
---|---|
Pages (from-to) | 502-509 |
Number of pages | 8 |
Journal | Journal of andrology |
Volume | 27 |
Issue number | 4 |
DOIs | |
State | Published - Jul 2006 |
Keywords
- Enzyme
- Gene expression
- Glycolysis
- Ovary
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Reproductive Medicine
- Endocrinology
- Urology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Testis-specific lactate dehydrogenase (LDH-C4; Ldh3) in murine oocytes and preimplantation embryos'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Testis-specific lactate dehydrogenase (LDH-C4; Ldh3) in murine oocytes and preimplantation embryos. / Coonrod, Scott; Vitale, Alejandra; Duan, Chongwen et al.
In: Journal of andrology, Vol. 27, No. 4, 07.2006, p. 502-509.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Testis-specific lactate dehydrogenase (LDH-C4; Ldh3) in murine oocytes and preimplantation embryos
AU - Coonrod, Scott
AU - Vitale, Alejandra
AU - Duan, Chongwen
AU - Bristol-Gould, Sarah
AU - Herr, John
AU - Goldberg, Erwin
N1 - Funding Information: M.A.K. is funded by an NIHR Research Professorship and receives funding from the Sir Jules Thorn Award for Biomedical Research, Great Ormond Street Children’s Hospital Charity (GOSHCC) and Rosetrees Trust. M.A.K., K.E.B., L.A., D.S., A.N., N.T. and E.M. are supported by the NIHR GOSH BRC. K.M.G. received funding from Temple Street Foundation. L.A. is funded by the Swiss National Foundation. E.M. received funding from the Rosetrees Trust (CD-A53), and the Great Ormond Street Hospital Children’s Charity. A.S.J. is funded by NIHR Bioresource for Rare Diseases. S.A.I. and M.H. are supported by the NINDS Intramural program. K.P.B. is PI of the Movement disorders centre (MDC) at UCL, Institute of Neurology which has been funded by the BRC. He has grant support by EU Horizon 2020. M.E.D-H. has clinical training grant through Tourette Association of America, but the research is unrelated to KMT2B. T.L. received funding from Health Research Board, Ireland and Michael J Fox. Foundation. K.A.M. receives funding from the NIH (award number K23NS101096-01A1). N.S. receives funding from the NIH (award number NS 087997 0). D.D. was supported by KIM MUSE Biomarkers and Therapy study grant during this work. B.B.A.d.V. financially supported by grants from the Netherlands Organization for Health Research and Development (912-12-109). J.F. is funded by the Rady Children’s Institute for Genomic Medicine. F.L.R. is funded by Cambridge Biomedical Research Centre. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute [grant number WT098051]. This research Funding Information: We thank all our patients and their families for taking part in this study. This research was supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. We also acknowledge support from the UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s and St. Thomas’ National Health Service (NHS) Foundation Trust in partnership with King’s College London. The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Department of Health or Wellcome Trust. Sequencing for Patient 37 was provided by the University of Washington Center for Mendelian Genomics (UW-CMG) and was funded by the National Human Genome Research Institute and the National Heart, Lung and Blood Institute grant HG006493 to Drs Debbie Nickerson, Michael Bamshad, and Suzanne Leal. Funding Information: We thank all our patients and their families for taking part in this study. This research was supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. We also acknowledge support from the UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust in partnership with King's College London. The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, Department of Health or Wellcome Trust. Sequencing for Patient 37 was provided by the University of Washington Center for Mendelian Genomics (UW-CMG) and was funded by the National Human Genome Research Institute and the National Heart, Lung and Blood Institute grant HG006493 to Drs Debbie Nickerson, Michael Bamshad, and Suzanne Leal. M.A.K. is funded by an NIHR Research Professorship and receives funding from the Sir Jules Thorn Award for Biomedical Research, Great Ormond Street Children's Hospital Charity (GOSHCC) and Rosetrees Trust. M.A.K., K.E.B., L.A., D.S., A.N., N.T. and E.M. are supported by the NIHR GOSH BRC. K.M.G. received funding from Temple Street Foundation. L.A. is funded by the Swiss National Foundation. E.M. received funding from the Rosetrees Trust (CD-A53), and the Great Ormond Street Hospital Children's Charity. A.S.J. is funded by NIHR Bioresource for Rare Diseases. S.A.I. and M.H. are supported by the NINDS Intramural program. K.P.B. is PI of the Movement disorders centre (MDC) at UCL, Institute of Neurology which has been funded by the BRC. He has grant support by EU Horizon 2020. M.E.D-H. has clinical training grant through Tourette Association of America, but the research is unrelated to KMT2B. T.L. received funding from Health Research Board, Ireland and Michael J Fox. Foundation. K.A.M. receives funding from the NIH (award number K23NS101096-01A1). N.S. receives funding from the NIH (award number NS 087997 0). D.D. was supported by KIM MUSE Biomarkers and Therapy study grant during this work. B.B.A.d.V. financially supported by grants from the Netherlands Organization for Health Research and Development (912-12-109). J.F. is funded by the Rady Children's Institute for Genomic Medicine. F.L.R. is funded by Cambridge Biomedical Research Centre. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute [grant number WT098051]. This research was made possible through access to the data and findings generated by the 100 000 Genomes Project (Patient 34). The 100 000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health). The 100 000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100 000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. Research reported in this manuscript was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director to the Undiagnosed Disease Network (UDN) and the NIH Undiagnosed Disease Program (Award numbers: U01HG007690 and U01HG007703). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: was made possible through access to the data and findings generated by the 100 000 Genomes Project (Patient 34). The 100 000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health). The 100 000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100 000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. Research reported in this manuscript was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director to the Undiagnosed Disease Network (UDN) and the NIH Undiagnosed Disease Program (Award numbers: U01HG007690 and U01HG007703). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
PY - 2006/7
Y1 - 2006/7
N2 - LDH-C4 (Ldh3) is a member of the lactate dehydrogenase family of isozymes that catalyze the terminal reaction in the glycolytic pathway. In mammals, 3 genes, Idha, Idhb, and Ldhc, encode the subunits that assemble into catalytically active homo- and heterotetramers. Differential expression of these genes determines the lactate dehydrogenase (LDH) isozyme composition of tissues, and, as is well known, A subunits predominate in skeletal muscle and B subunits are abundantly produced in brain and heart, with the Ldh2 isozyme the most abundant form in oocytes. The C peptide can be detected first in pachytene spermatocytes and constitutes the primary LDH of spermatozoa. Originally the Ldhc gene (Ldh3 in terminology applied to murine cells) was considered to be testis specific on the basis of immunochemical, enzymatic, and molecular analyses. Here we report the detection of this isozyme in the murine oocyte and early embryo. Our results indicate that Ldh3 mRNA is transcribed in oocytes and cannot be detected in fertilized eggs. Ldh3 protein, however, persists to the blastocyst stage of embryonic development localizing mainly to the cortex region of oocytes, eggs, zygotes, and embryonic blastomeres.
AB - LDH-C4 (Ldh3) is a member of the lactate dehydrogenase family of isozymes that catalyze the terminal reaction in the glycolytic pathway. In mammals, 3 genes, Idha, Idhb, and Ldhc, encode the subunits that assemble into catalytically active homo- and heterotetramers. Differential expression of these genes determines the lactate dehydrogenase (LDH) isozyme composition of tissues, and, as is well known, A subunits predominate in skeletal muscle and B subunits are abundantly produced in brain and heart, with the Ldh2 isozyme the most abundant form in oocytes. The C peptide can be detected first in pachytene spermatocytes and constitutes the primary LDH of spermatozoa. Originally the Ldhc gene (Ldh3 in terminology applied to murine cells) was considered to be testis specific on the basis of immunochemical, enzymatic, and molecular analyses. Here we report the detection of this isozyme in the murine oocyte and early embryo. Our results indicate that Ldh3 mRNA is transcribed in oocytes and cannot be detected in fertilized eggs. Ldh3 protein, however, persists to the blastocyst stage of embryonic development localizing mainly to the cortex region of oocytes, eggs, zygotes, and embryonic blastomeres.
KW - Enzyme
KW - Gene expression
KW - Glycolysis
KW - Ovary
UR - http://www.scopus.com/inward/record.url?scp=33746316500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746316500&partnerID=8YFLogxK
U2 - 10.2164/jandrol.05185
DO - 10.2164/jandrol.05185
M3 - Article
C2 - 16582413
AN - SCOPUS:33746316500
SN - 0196-3635
VL - 27
SP - 502
EP - 509
JO - Journal of Andrology
JF - Journal of Andrology
IS - 4
ER -